Skip to content
The Peptide Effect
preclinicalCognitive Enhancement

P21

Also known as: P021, CNTF-derived peptide, Compound 021

P21 (also designated P021) is a small neurotrophic compound derived from the active region of ciliary neurotrophic factor (CNTF). Developed at the New York State Institute for Basic Research in Developmental Disabilities, P21 was designed to cross the blood-brain barrier and provide CNTF-like neurotrophic benefits without the systemic side effects of full-length CNTF. In animal models of Alzheimer's disease, P21 has demonstrated neurogenesis in the hippocampal dentate gyrus, BDNF upregulation, and reduction in tau pathology. It remains at an extremely early stage of research with no human clinical trials conducted.

Key Facts

Mechanism
P21 is a small peptide derived from the most active region of ciliary neurotrophic factor (CNTF), modified with adamantylated amino acids to enhance blood-brain barrier penetration and metabolic stability. It promotes neurogenesis primarily in the dentate gyrus of the hippocampus by increasing brain-derived neurotrophic factor (BDNF) expression. P21 also inhibits leukemia inhibitory factor (LIF) signaling, which normally suppresses neuronal differentiation of neural progenitor cells. By simultaneously increasing pro-neurogenic (BDNF) and decreasing anti-neurogenic (LIF) signals, P21 shifts the balance toward new neuron production. Additionally, it reduces abnormal tau hyperphosphorylation and neurofibrillary tangle formation in Alzheimer's mouse models.
Research Status
preclinical
Half-Life
Not established
Primary Use
Cognitive Enhancement
Table of Contents

Benefits

  • Enhances hippocampal neurogenesis — promotes new neuron formation in the dentate gyrus, a brain region critical for memory formation and spatial navigationpreliminary
  • Memory improvement in Alzheimer's mouse models — reverses learning and memory deficits in transgenic AD mice when administered over several weekspreliminary
  • Promotes BDNF production — upregulates brain-derived neurotrophic factor expression in the hippocampus, supporting neuronal health and synaptic plasticitypreliminary
  • Blood-brain barrier penetrant — specifically engineered to cross the BBB, unlike full-length CNTF which cannot, making it suitable for systemic administrationpreliminary
  • Reduces tau pathology — decreases abnormal tau hyperphosphorylation and neurofibrillary tangle density in animal models of tauopathypreliminary
  • Inhibits LIF-mediated suppression of neurogenesis — removes a key brake on neural progenitor cell differentiation, complementing its BDNF-enhancing effectspreliminary

Dosage Protocols

RouteDosage RangeFrequencyNotes
Intranasal1–2 mg dailyOnce dailyWARNING: No human clinical dosing has been established. Intranasal is the most commonly reported route among experimental users. Animal studies used oral administration at doses not directly translatable to humans.
Subcutaneous injection1–2 mg dailyOnce dailySome users prefer subcutaneous injection for potentially more reliable absorption. No clinical data validates this route or dose in humans.
Oral (animal research)60 mcg/mL in drinking water (mouse studies)Continuous in animal studies for 30+ daysAnimal research used chronic oral administration over 1–3 months. The adamantylated amino acid modifications were specifically designed to enable oral bioavailability.

Medical disclaimer

Dosage information is provided for educational reference only. Always follow your prescriber's instructions and consult a qualified healthcare provider before starting any peptide protocol.

Side Effects

  • Very limited safety data — no human clinical trials have been conducted; the complete side effect profile is unknown and cannot be predicted from animal studies aloneserious
  • Headache — reported anecdotally by users in online communities; no clinical characterization availablecommon
  • Fatigue — mild tiredness reported anecdotally; unclear if related to the compound or confounding factorscommon
  • Unknown long-term effects of enhanced neurogenesis — chronic stimulation of neural progenitor cell proliferation could theoretically have unintended consequencesserious

Explore next

Frequently Asked Questions

How does P21 compare to Dihexa?
P21 and Dihexa are both preclinical nootropic compounds aimed at enhancing cognitive function, but they work through entirely different mechanisms. P21 is a CNTF-derived peptide that promotes neurogenesis via BDNF upregulation and LIF inhibition — essentially growing new neurons. Dihexa is an HGF mimetic that promotes synaptogenesis via c-Met activation — strengthening connections between existing neurons. P21's mechanism is generally considered to carry lower cancer risk than Dihexa's c-Met pathway, as BDNF/CNTF signaling is less directly linked to oncogenesis. Both have extremely limited human data and should be considered highly experimental.
Is P21 actually promoting neurogenesis in the human brain?
The honest answer is that we do not know. P21 has convincingly demonstrated hippocampal neurogenesis in mouse models of Alzheimer's disease, with histological evidence of new neuron formation in the dentate gyrus. However, adult human neurogenesis is itself a topic of ongoing scientific debate — its extent and significance in the adult human hippocampus remains controversial. Even if P21 does promote neurogenesis in humans, the functional significance of new neurons and whether they integrate into existing circuits meaningfully is unclear. No human imaging or biomarker studies have been conducted with P21.
Does P21 cross the blood-brain barrier?
Yes, P21 was specifically engineered to cross the blood-brain barrier (BBB), which is one of its key design advantages over full-length CNTF. The incorporation of adamantylated amino acid residues into the peptide structure increases its lipophilicity and BBB permeability. In animal studies, systemically administered P21 produced measurable increases in hippocampal BDNF levels and dentate gyrus neurogenesis, confirming CNS penetration. This BBB penetrance allows for non-invasive administration routes (oral, intranasal, subcutaneous) rather than requiring direct brain injection.
How early-stage is P21 research really?
P21 is at a very early stage — squarely in preclinical research. All published studies have been conducted in mice, primarily transgenic Alzheimer's disease models. There have been no Phase 1 safety studies, no pharmacokinetic studies in humans, no dose-finding studies, and no efficacy trials. The published research comes primarily from one laboratory group. While the results in mouse models are promising, the translation rate from promising animal cognitive studies to successful human therapies is historically very low. Anyone using P21 is essentially self-experimenting with a compound that has not been tested for safety in humans at any dose.
Where can I find P21 and is it reliable?
P21 is available only through unregulated research chemical suppliers. There is no pharmaceutical-grade manufacturing, no quality control oversight, and no standardized formulations. The market for P21 is significantly smaller than for more popular peptides, which means fewer suppliers and less competitive pressure on quality. Certificate of analysis (COA) verification from independent third-party laboratories is essential. Users should be aware that product purity, potency, and even identity cannot be guaranteed. The research compound should not be confused with the p21 tumor suppressor protein (CDKN1A), which is an entirely different molecule.

References

  1. 1
    A neurogenic compound P021 enhances dentate gyrus neurogenesis and rescues cognitive deficits in 3×Tg-AD mouse model of Alzheimer's disease(2013)PubMed ↗
  2. 2
    Chronic treatment with a neurotrophic compound P021 rescues cognitive deficits and promotes neurogenesis in aging(2015)PubMed ↗
  3. 3
    P021 — a CNTF-derived peptide — prevents tau abnormalities and cognitive deficit in Alzheimer's disease model mice(2016)PubMed ↗
  4. 4
    Small-molecule CNTF mimetics: design, synthesis, and neurotrophic activity of P021-derived compounds(2011)PubMed ↗

Last updated: 2026-02-14